Indian pharma kings loosen family ties at the top
This article was originally published in Scrip
Leaders from innovator companies have been making the move to Indian generics companies. What does that mean for the evolving industry in the region, and how easy is it to adjust to leading a family business as the outsider? Anju Ghangurde finds out.
You may also be interested in...
New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.
Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…